Get the Stockscreener App
6.52
0.15%
0.010
After Hours:
6.51
-0.010
-0.15%
Eupraxia Pharmaceuticals Inc stock is traded at $6.52, with a volume of 250.47K.
It is up +0.15% in the last 24 hours and down -2.54% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
See More
Previous Close:
$6.51
Open:
$6.4
24h Volume:
250.47K
Relative Volume:
0.80
Market Cap:
$425.93M
Revenue:
-
Net Income/Loss:
$-44.47M
P/E Ratio:
-6.4041
EPS:
-1.0181
Net Cash Flow:
$-33.50M
1W Performance:
+6.89%
1M Performance:
-2.54%
6M Performance:
-25.82%
1Y Performance:
+21.19%
1-Day Range:
$6.36
$6.645
1-Week Range:
$5.79
$6.74
52-Week Range:
$5.04
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.52 | 403.07M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
478.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
760.66 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
844.50 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.46 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
323.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-23-26 | Initiated | William Blair | Outperform |
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
View All
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Why Eupraxia Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.810|Chg%:-0.490 - TradingKey
Eupraxia Pharmaceuticals, Inc. Revenue Breakdown – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals Inc (EPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Cash Flow - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.955|Chg%:+0.145 - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.910|Chg%:-0.390 - TradingKey
Eupraxia Pharmaceuticals (EPRX) Holds Steady Near Support Amid Low VolumeBullish Percent Index - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Q3 2024 earnings summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Bloom Burton & Co. Healthcare Investor Conference 2026 summary - Quartr
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
What's Going On With Eupraxia Pharmaceuticals Inc Stock Tuesday? - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Insider Stock Buying Reaches US$5.58m On Eupraxia Pharmaceuticals - simplywall.st
Why Eupraxia Pharmaceuticals Inc stock is plummeting today - Wealth Awesome
Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia names new executives, relocates operations By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone - TipRanks
Eupraxia names new executives, relocates operations - Investing.com
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - The Manila Times
Eupraxia Pharmaceuticals (NASDAQ: EPRX) adds senior leaders, prepares for Q4 2026 RESOLVE data - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is tanking today - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience – Key Levels to WatchLong Setup Ideas - dars.gov.et
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances - TipRanks
Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board - Stock Titan
Eupraxia Pharmaceuticals appoints three directors to board - Investing.com
Eupraxia Pharmaceuticals appoints three directors to board By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization - Investing News Network
EPRX Technical Analysis & Stock Price Forecast - Intellectia AI
EPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EPRX Technical Analysis & ETF Price Forecast - Intellectia AI
A3EGRS Forecast — Price Target — Prediction for 2027 - TradingView
Eupraxia Pharmaceuticals (EPRX) Gains Momentum, Testing Key Resistance LevelsCall Flow Alert - dars.gov.et
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:EPRX) - TradingView
EPRX Forecast — Price Target — Prediction for 2027 - TradingView
Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (FWB:X43) - TradingView
Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17 - Moomoo
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):